X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs DIVIS LABORATORIES - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA DIVIS LABORATORIES DISHMAN PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 25.1 35.5 70.7% View Chart
P/BV x 3.3 6.9 48.5% View Chart
Dividend Yield % 0.7 0.7 102.1%  

Financials

 DISHMAN PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
DIVIS LABORATORIES
Mar-18
DISHMAN PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3741,142 32.8%   
Low Rs129533 24.2%   
Sales per share (Unadj.) Rs197.8146.6 134.9%  
Earnings per share (Unadj.) Rs21.233.0 64.2%  
Cash flow per share (Unadj.) Rs34.738.4 90.4%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.81.2 66.6%  
Book value per share (Unadj.) Rs179.9222.8 80.7%  
Shares outstanding (eoy) m80.69265.47 30.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.35.7 22.3%   
Avg P/E ratio x11.925.3 46.8%  
P/CF ratio (eoy) x7.221.8 33.2%  
Price / Book Value ratio x1.43.8 37.2%  
Dividend payout %9.430.3 31.2%   
Avg Mkt Cap Rs m20,306222,318 9.1%   
No. of employees `0000.810.8 7.7%   
Total wages/salary Rs m5,3554,561 117.4%   
Avg. sales/employee Rs Th19,252.73,616.0 532.4%   
Avg. wages/employee Rs Th6,459.5423.8 1,524.3%   
Avg. net profit/employee Rs Th2,064.1814.9 253.3%   
INCOME DATA
Net Sales Rs m15,96138,915 41.0%  
Other income Rs m2651,134 23.4%   
Total revenues Rs m16,22640,049 40.5%   
Gross profit Rs m4,10312,617 32.5%  
Depreciation Rs m1,0911,425 76.5%   
Interest Rs m94413 7,100.8%   
Profit before tax Rs m2,33412,313 19.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6243,543 17.6%   
Profit after tax Rs m1,7118,770 19.5%  
Gross profit margin %25.732.4 79.3%  
Effective tax rate %26.728.8 92.9%   
Net profit margin %10.722.5 47.6%  
BALANCE SHEET DATA
Current assets Rs m11,01845,351 24.3%   
Current liabilities Rs m9,5176,507 146.3%   
Net working cap to sales %9.499.8 9.4%  
Current ratio x1.27.0 16.6%  
Inventory Days Days110127 87.2%  
Debtors Days Days3595 36.6%  
Net fixed assets Rs m16,30421,160 77.1%   
Share capital Rs m161531 30.4%   
"Free" reserves Rs m12,90758,625 22.0%   
Net worth Rs m14,51659,156 24.5%   
Long term debt Rs m4,1890-   
Total assets Rs m29,80567,832 43.9%  
Interest coverage x3.5926.8 0.4%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.50.6 93.3%   
Return on assets %8.912.9 68.8%  
Return on equity %11.814.8 79.5%  
Return on capital %17.520.8 84.1%  
Exports to sales %24.80-   
Imports to sales %3.721.8 17.1%   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m5968,485 7.0%   
Fx inflow Rs m4,95232,359 15.3%   
Fx outflow Rs m6979,042 7.7%   
Net fx Rs m4,25523,317 18.2%   
CASH FLOW
From Operations Rs m2,7867,759 35.9%  
From Investments Rs m-1,529-4,783 32.0%  
From Financial Activity Rs m-941-3,142 30.0%  
Net Cashflow Rs m316-166 -190.6%  

Share Holding

Indian Promoters % 61.4 52.0 118.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 11.8 31.4%  
FIIs % 12.7 19.0 66.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 17.2 128.5%  
Shareholders   46,261 31,796 145.5%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ORCHID PHARMA LTD  CIPLA  ABBOTT INDIA  SUVEN LIFE  J.B.CHEMICALS  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 260 Points Down; TCS & Infosys Top Losers(12:30 pm)

Stock markets in India are presently trading lower, tracking weakness in their global peers. Among the sectoral indices, IT stocks and metal stocks are witnessing maximum selling pressure.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS